SpectRx
This article was originally published in The Gray Sheet
Executive Summary
Pivotal trials of firm's non-invasive, biophotonic cervical cancer test are expected to begin by early 2003. SpectRx announces July 9 that protocols have been submitted to FDA. Preliminary data from a National Cancer Institute study in 274 women showed a prototype test detected 15% more high-grade "pre-cancers" than standard Pap tests, and could potentially cut by half the number of false positives detected by human papilloma virus (HPV) tests. Previously, the device demonstrated a sensitivity of 92% and specificity of 80%, versus sensitivity of 76% and specificity of 80% for the thin-layer Pap test, according to SpectRx (1"The Gray Sheet" April 22, 2002, In Brief)...
You may also be interested in...
SpectRx cancer assay
Pivotal clinical trials for the non-invasive cervical cancer detection device will begin by early 2003, SpectRx announces April 15. Clinical results indicate that the third-generation device detects 17% more high-grade pre-cancer compared to thin-layer Pap tests and 28% more than traditional Pap tests. The device also boasts a sensitivity of 92% and specificity of 80%, versus sensitivity of 76% and specificity of 80% for the thin-layer Pap test when compared to colposcopy and histopathology, the firm claims (1"The Gray Sheet" April 17, 2000, p. 18)...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.